名稱： 色瑞替尼
英文名： Ceritinib
CAS號(hào)： 1032900-25-6

產(chǎn)品描述：

• ：

• 色瑞替尼

• 中文別名：

• 5-氯-N2-(2-異丙氧基-5-甲基-4-(哌啶-4-基)苯基)-N4-(2-(異丙基磺?；?苯基)嘧啶-2,4-二胺

• 英文名稱：

• Ceritinib

• 英文別名：

• CS-1406;

  LDK378;

  5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-ylphenyl)-N4-[2-(isopropylsulfonyl)phenyl]-pyrimidine-2,4-diamine;

  Ceritinib (LDK378);

  5-chloro-2-N-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine;

  查看更多英文別名

• CAS號(hào)：

• 1032900-25-6

• 分子式：

• C28H36ClN5O3S

• 分子量：

• 558.13500

• 精確質(zhì)量：

• 557.22300

Ceritinib (INN, trade name Zykadia) is a drug for the treatment of a specific type of lung cancer. It is an anaplastic lymphoma kinase (ALK) inhibitor. It was developed by Novartis. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) in patients that failed treatment with crizotinib. It is a more effective, but more toxic, alternative to traditional platinum-based chemotherapies. Ceritinib was found at physiological concentrations to inhibit ALK, insulin-like growth factor 1 receptor (IGF-1R), and ROS1